Ignite Creation Date:
2024-05-06 @ 8:42 AM
Last Modification Date:
2024-10-26 @ 12:04 PM
Study NCT ID:
NCT02807558
Status:
COMPLETED
Last Update Posted:
2024-01-19
First Post:
2016-06-13
Brief Title:
A Biomarker-Directed Phase 2 Trial of Tamibarotene SY-1425 in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Sponsor:
Syros Pharmaceuticals
Organization:
Syros Pharmaceuticals
Study Overview
Official Title:
A Biomarker-Directed Phase 2 Trial of SY-1425 a Selective Retinoic Acid Receptor Alpha Agonist in Adult Patients With Acute Myeloid Leukemia AML or Myelodysplastic Syndrome MDS
Status:
COMPLETED
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the activity of tamibarotene in participants with relapsedrefractory RR AML administered as a monotherapy or in combination with azacitidine RR higher-risk MDS HR-MDS administered as a monotherapy or in combination with daratumumab newly diagnosed treatment naïve AML participants who are unlikely to tolerate standard intensive chemotherapy administered as a monotherapy or in combination with azacitidine or lower-risk MDS LR-MDS administered as a monotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2017-000783-14 | EUDRACT_NUMBER | None | None |